Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
WEAN-HF: Withdrawal of GDMT in Recovered Tachycardia-induced Cardiomyopathy
NCT06128980Phase 3Recruiting
- Sponsor
- Herlev & Gentofte Hospital
- Start
- Jan 2025
- Primary completion
- Jan 2028
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial in heart failure (HF) (2 arms), sponsored by Herlev & Gentofte Hospital. Primary endpoint: Patients free from heart failure deterioration at 1 year. Started Jan 2025; status: recruiting.
02
Conditions
heart failure (HF)
Beyond the preview
Go deeper on NCT06128980.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06128980.